Omadacycline, the drug that US FDA approved for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is not susceptible to common tetracycline-resistancemechanisms, and has demonstrated efficacy against a broad spectrum of pathogens including resistant isolates, which are increasing in prevalence and complexity.
Omadacycline is a potent an demonstrates efficacy against both Bacillus anthracis and Yersinia pestis; Also, it is a novel aminomethylcycline antibiotic in clinical development for community-acquired bacterial pneumonia (CABP).
ChEBI: Omadacycline is a member of tetracyclines.
Omadacycline has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections.The in vitro activity of Omadacycline against clinically relevant anaerobes was similar to that of tigecycline, with MIC90 values of 1 to 8 g/ml against Bacteroides spp, 0.5 g/ml against Clostridium difficile, Prevotella spp., and Porphyromonas asaccharolytica,1 g/ml against Peptostreptococcus spp, and 16 g/ml against Clostridium perfringens.
OMadacycline may cause serious adverse reactions including hypersensitivity reactions, tooth discoloration,Clostridioides difficile-associated diarrhea, and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy.Common adverse reactions include nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.Mild to moderate nausea and vomiting were the most frequent treatment-emergent adverse events in omadacycline (111 [30%] of 368 and 62 [17%] of 368, respectively) groups.
